Myeloproliferative Neoplasms (MPN)
Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term?
The clinicopathology of MDS and MPN are not mutually exclusive and for this reason the category of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) exists. Several sub-entities have been included under the MDS/MPN umbrella, including MDS/MPN-unclassifiable (MDS/MPN-U) for those cases whose morphologic and clinical phenotype do not meet criteria to be classified as any other MDS/MPN sub-entity.
Ellen Ritchie, MD
Nikolai Podoltsev, MD, PhD
Thomas Prebet, MD, PhD
Catriona Jamison, MD, PhD
Guidance for Bone Marrow Failure Patients to Protect Against Coronavirus (COVID-19)
This content has been prepared in consultation with AAMDSIF Medical Advisory Board Chair Mikkael Sekeres MD, MS of Sylvester Comprehensive Cancer Center, University of Miami and Co-Chair Olatoyosi Odenike MD of the University of Chicago with additional review by Amy DeZern, MD, Johns Hopkins and Carlos De Castro, MD, Duke. ( November 2022)
Luspatercept-aamt
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia anemia: (uh-NEE-mee-uh) A condition in which
